Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN

NCT03726775 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

61

Enrollment

OTHER

Sponsor class

Conditions

HNSCC

Interventions

DRUG: Durvalumab

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou

Collaborators

[object Object]
[object Object]